^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FOLH1 positive

    i
    Other names: FOLH1, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, Folate hydrolase 1, prostate-specific membrane antigen
    Entrez ID:
    2346
    Related biomarkers:
    Expression
    2d
    Prostate-Specific Membrane Antigen (PSMA): A Potential Theranostic Biomarker in Breast Cancer. (PubMed, Biomedicines)
    Our results suggest that PSMA could be used as a biomarker in BC, given that it is highly expressed in more aggressive tumors. These findings open the way to a clinical investigation for the possible use of PSMA as a theranostic biomarker in BC patients with PSMA positive PET scan.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression • FOLH1 positive
    9d
    PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan (clinicaltrials.gov)
    P=N/A, N=753, Not yet recruiting, Novartis Pharmaceuticals
    New trial
    |
    FOLH1 positive
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    9d
    Comparative evaluation of [¹⁸F]FAPI-42 and [¹⁸F]PSMA-1007 PET/CT for lesion detection and uptake in prostate cancer across disease stages. (PubMed, EJNMMI Res)
    While [¹⁸F]PSMA 1007 PET/CT remains superior for overall lesion detection, [¹⁸F]FAPI 42 PET/CT may provide complementary value in selected scenarios, particularly in subsets with reduced PSMA expression.
    Journal
    |
    FOLH1 (Folate hydrolase 1) • FAP (Fibroblast activation protein, alpha)
    |
    FOLH1 expression • FOLH1 positive
    13d
    Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC (clinicaltrials.gov)
    P2, N=12, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
    New P2 trial
    |
    FOLH1 positive
    18d
    A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC (clinicaltrials.gov)
    P1/2, N=73, Recruiting, Radiopharm Theranostics, Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FOLH1 positive
    24d
    A One-Step Workflow for Size-Based Separation of Extracellular Vesicles With Integrated Surface Marker Detection. (PubMed, J Extracell Biol)
    Proof-of-concept was gained for the detection of PSMA-positive EVs in urine from prostate cancer patients and discrimination of breast cancer patients from healthy donors by quantifying EpCAM- or HER2-positive EVs in blood plasma. In conclusion, using low-volume biofluids, the one-step AF4-MALS-FLD workflow holds potential for fast and robust EV biomarker detection.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • EPCAM (Epithelial cell adhesion molecule) • CD9 (CD9 Molecule) • CD81 (CD81 Molecule)
    |
    HER-2 positive • FOLH1 positive
    26d
    PSMACare: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2030 --> Dec 2026 | Trial primary completion date: Apr 2028 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    FOLH1 positive
    |
    Xtandi (enzalutamide) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    1m
    APEX-01: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=183, Active, not recruiting, Janssen Research & Development, LLC | N=50 --> 183
    Enrollment change • First-in-human
    |
    FOLH1 positive
    |
    abiraterone acetate • prednisone • apalutamide • JNJ-8177
    1m
    Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer (clinicaltrials.gov)
    P1, N=6, Recruiting, C Ray Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FOLH1 positive
    1m
    Prostate specific membrane antigen-targeted multimodal imaging nanobubbles with ultrasound irradiation inhibit prostate cancer growth via autophagy activation. (PubMed, Acta Biomater)
    Under ultrasound irradiation, the targeted nanobubbles successfully activate autophagy and exert an anti-tumor effect through inducing autophagy-related cell death. The targeted nanobubbles demonstrate specific accumulation in PSMA-positive tumors, dynamic monitoring therapy, and significantly amplified therapeutic efficacy against prostate cancer, bringing a non-invasive, promising approach for prostate cancer therapy.
    Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 positive
    1m
    PROSTACT: The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only (clinicaltrials.gov)
    P3, N=16, Terminated, Telix Pharmaceuticals (Innovations) Pty Ltd | N=392 --> 16 | Trial completion date: Dec 2028 --> Jul 2025 | Recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Jul 2025; Telix is conducting a separate Phase 3 clinical trial - ProstACT Global NCT06520345- to expedite the development and approval process under an IND. Consequently, this necessitates the closure of the current 177Lu-TLX591-002 Phase 3 trial.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    FOLH1 positive
    |
    docetaxel • Xtandi (enzalutamide) • 177Lu-rosopatamab tetraxetan (TLX591)
    1m
    Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). (clinicaltrials.gov)
    P1/2, N=100, Recruiting, AdvanCell Pty Limited | Trial completion date: Dec 2029 --> Jun 2029 | Trial primary completion date: Dec 2027 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    FOLH1 positive